PredictaChart by Predicta Med is an innovative medical record summary tool designed to enhance clinical efficiency and decision-making. This AI-powered solution leverages natural language processing (NLP) to extract and prioritize key information from vast volumes of clinical notes, ensuring that physicians focus on the most relevant data.

Key Features and Benefits:

Content Prioritization for Efficiency

PredictaChart creates a concise, specialty-specific view of a patient's clinical information, tailored to their conditions. This prioritization reduces the time required for chart reviews and allows physicians to concentrate on critical issues.

AI-Driven Insights

Using advanced NLP, the tool identifies vital information often buried within extensive records from multiple providers, making patient health data more accessible and actionable.

Improved Clinical Decision-Making

By highlighting urgent or relevant issues, PredictaChart supports faster, patient-specific decision-making. It empowers clinicians with better insights to address the unique needs of each patient.

Enhanced Patient Care

The tool accelerates diagnosis and treatment by streamlining access to vital information. Automated checks for inconsistencies or missing data reduce the risk of errors, contributing to more precise and effective care.

PredictaChart transforms how specialists interact with medical records, helping them save time, improve accuracy, and deliver optimal patient outcomes.

Predicta Med is transforming the care of autoimmune diseases by offering an EMR-integrated platform that accelerates diagnosis and intervention. The platform includes three core modules:

• PredictaAI: The first AI-driven solution designed for early detection and tailored intervention of autoimmune diseases, enhancing diagnostic accuracy and speed.
• PredictaChart: The tool streamlines clinical decision-making, significantly reducing the time spent on patient chart reviews.
• PredictaMatch: A patient eligibility assessment tool, seamlessly embedded in EMRs, providing healthcare providers with relevant treatment options based on a patient’s disease profile.

Together, these modules enable faster, more accurate care decisions, improving outcomes for patients with autoimmune diseases

Web-based clinical intelligence platform, primarily utilized in critical care units to guide clinical decisions. The platform has full interoperability with the Electronic Health Record, and combines all relevant data within the complex critical care environment into one visualization to provide a full picture of a patient and their longitudinal trends. FDA-cleared algorithms continually assess the incoming patient information and provide early warning signs of clinical deterioration to aid care teams with determining interventions and treatment. Automated clinical workflows, customized to each individual ICU, provide care efficiency and positively impact clinical outcomes. 

Published clinical outcomes showing:

• Up to 36% reduction in ICU length of stay
• 41% reduction in ICU readmissions
• 22% reduction in time on ventilation
• 18% reduction in time on vasoactive medication

Commercial stage company with market leading AI clinical decision support platform for bedside and remote monitoring of high acuity patients. Published outcomes and strong ROI; utilized in 40+ hospitals & health systems.

The tool streamlines clinical decision-making, significantly reducing the time spent on patient chart reviews

Established partnerships with global experts specialists.  

Domain expertise in specialty diseases and specialty care.

Trained & validated on proprietary specialty care specific large data sets.

Seamless EMR integration.

Etiometry provides functionality to seamlessly extend the EHR to be effective for care in high-acuity patient settings (e.g. ICU), including automating clinical workflows, and providing in-depth, longitudinal trends.

Etiometry is the only CDS platform with 4 FDA-cleared risk algorithms and the platform's data collection capabilities have led to a vastly larger number of supporting clinical studies (>150).